Table 1.
Characteristics of Study Sample
| Characteristics | N=2652 |
|---|---|
| Age, y | 66±9 |
| Men, % | 44.8 |
| Height, cm | 166.9±10 |
| Weight, kg | 78.8±18 |
| Systolic blood pressure, mm Hg | 128±17 |
| Diastolic blood pressure, mm Hg | 74±10 |
| Use of antihypertensive medication, % | 47.5 |
| Heart rate, bpm | 59.6±10 |
| Diabetes mellitus, % | 3.1 |
| Current smoking, % | 9.1 |
| LDL‐C, mg/dL | 105.8±31 |
| HDL‐C, mg/dL | 57.7±18 |
| Triglycerides, mg/dL | 117.5±69 |
| Total cholesterol, mg/dL | 186.6±37 |
| Lipid lowering medication use, % | 42.1 |
| eGFR, mL/min/1.73 m2 | 77.8±16 |
| Prior heart failure, % | 2.38 |
| Plasma ceramide concentrations | |
| Plasma C16:0 ceramide, μg/mL | 0.2±0.04 |
| Plasma C24:0 ceramide, μg/mL | 2.3±0.7 |
| Plasma C16/24 ceramide, μg/mL | 0.08±0.02 |
| Echocardiographic measures | |
| LV mass index, g | 162.2 (134.5, 162.6) |
| LV ejection fraction, % | 67.3 (62.9, 71.7) |
| Left atrial emptying fraction, % | 48 (46, 50) |
| Left atrial end‐systolic volume, mL | 56.8±19.3 |
| LV global longitudinal strain, % | −20.6±3 |
| LV global circumferential strain, % | −31.9±6 |
| E/e′ | 6.6 (5.5, 8.1) |
Values are mean±standard deviation, median (Q1, Q3), or percentage. E/e′ indicates mitral inflow velocity to early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LV, left ventricular.